ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First Patient Dosed in Biomarker-Guided Study of DB102 for Newly-Diagnosed Glioblastoma
January 15, 2021Denovo Biopharma announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma ... -
Denovo Biopharma Announces Breakthrough Discovery of Liafensine for Depression
March 13, 2020Denovo Biopharma has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. -
Denovo Biopharma Receives Global Rights to Novel Late-Stage Drug for Alzheimer's Disease
June 21, 2019Denovo Biopharma has licensed ORM-12741 from Orion Corporation. Denovo gains global rights to develop, manufacture and commercialize ORM-12741.
Pharma Sources Insight January 2025
